(+/-)-1-(carboxymethyl)-3-amino-2-pyrrolidone | 77591-07-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (+/-)-1-(carboxymethyl)-3-amino-2-pyrrolidone
• 英文别名: 2-(3-amino-2-oxopyrrolidin-1-yl)acetic acid；Amino-2-oxo-1-pyrrolidineacetic acid
• CAS: 77591-07-2
• 化学式: C₆H₁₀N₂O₃
• 分子量: 158.157
• InChiKey: ZMCJOKMEFYSAOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  、 (+/-)-1-(carboxymethyl)-3-amino-2-pyrrolidone 在 N,N-二异丙基乙胺 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  WO2019222677A5

  摘要：

  公开号：

  WO2019222677A5
• 作为产物：
  描述：

  1-<(benzyloxycarbonyl)methyl>-3-amino-2-pyrrolidone trifluoroacetate 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 水 为溶剂， 生成 (+/-)-1-(carboxymethyl)-3-amino-2-pyrrolidone
  参考文献：
  名称：

  Conformationally restricted inhibitors of angiotensin-converting enzyme. Synthesis and computations

  摘要：

  A series of inhibitors of angiotensin converting enzyme (ACE, dipeptidyl carboxypeptidase, EC 3.4.15.1) is described which addresses certain conformational aspects of the enzyme-inhibitor interaction. In this study the alanylproline portion of the potent ACE inhibitor enalaprilat (2) is replaced by a series of monocyclic lactams containing the required recognition and binding elements. In order to more fully assess the lactam ring conformations and the key backbone angle psi as defined in 3 with respect to possible enzyme-bound conformations, a series of model lactams was investigated with use of molecular mechanics. The results point to a correlation between inhibitor potency (IC50) and the computed psi angle for the lowest energy conformation of the model compounds. Thus the psi angle as defined in 3 is an important determinant in the binding of inhibitors to ACE. The inhibition data in conjunction with the computational data have served to define a window of psi angles from 130 degrees to 170 degrees which seems to be acceptable to the ACE active site.

  DOI：

  10.1021/jm00152a014

文献信息

• Bisaryl derivatives having FSH modulatory activity
  申请人：——

  公开号：US20040152703A1

  公开（公告）日：2004-08-05

  The invention relates to bisaryl derivatives of the formula I, 1 wherein (R,R) is selected from (H,H), O, (H,CH 3 ), (H,OH) and (H,CN); Ar is substituted phenyl and A is a group of formula II, III, IV or V: 2 An example is (3S,6S)-1-N-(7-phenylheptyl)-3-(4-(3,4,5-trimethoxyphenyl)benzyl)-4-N-methyl-6-methyl-2,5-dioxo-1,4-piperazine: 3 The compounds of the invention have FSH receptor modulatory activity and can be used for the control of fertility, for contraception or for treatment of hormone-dependent disorders.

  该发明涉及公式I的双芳基衍生物，其中(R,R)从(H,H)，O，(H,CH3)，(H,OH)和(H,CN)中选择；Ar是取代苯基，A是公式II，III，IV或V的基团之一：一个例子是(3S,6S)-1-N-(7-苯基庚基)-3-(4-(3,4,5-三甲氧基苯基)苯基)-4-N-甲基-6-甲基-2,5-二氧杂环己烷：该发明的化合物具有FSH受体调节活性，可用于控制生育、避孕或治疗激素依赖性疾病。
• 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors
  申请人：Borthwick David Alan

  公开号：US20070203206A1

  公开（公告）日：2007-08-30

  A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof.

  公式为（I）化合物及其药用可接受的盐、溶剂和可水解酯。
• Long lasting agonists and antagonists of LHRH and compositions containing them
  申请人：Merck & Co., Inc.

  公开号：EP0026640A2

  公开（公告）日：1981-04-08

  Novel peptides have the formula: in which A is (L or D)- pyroGlu, an (L or D)- (N-acetyl or N-pyroGlu) imino acid; acetyl D-Phe; or (C3-7 cycloalkyl)-acyl; B is His; Gly; or an L or D aromatic or aliphatic amino acid; or is absent; C is an (L or D) aromatic or aliphatic amino acid; D is Ser, Thr, or Ala; E is an aromatic amino acid; F is an amino acid with a basic side chain; G is an imino acid or aliphatic amino acid; X is GlyNH2; AlaNH2; aminoethyl; aminopropyl; or aminohydroxyethyl; Y is hydrogen or C1-4 alkyl; and n is 2 or3. Such peptides have long-lasting LHRH agonist and antagonist activity and are useful in promoting and reducing fertility. They may be included in suitable pharmaceutical compositions. Novel intermediate compounds have formulae: Compounds of formula: are made by alkylating basifying, and if necessary removing the protecting group from, compounds of formula: In these formulae, A is hydrogen or R3-O-CO-, R2 is C1-4 alkyl and R3 is C1-12 alkyl or C1-4 aralkyl.

  新型肽具有如下式子 其中 A 是 (L 或 D)- pyroGlu、(L 或 D)- (N-acetyl 或 N-pyroGlu)亚氨基 酸；乙酰基 D-Phe；或 (C3-7 环烷基)-乙酰基；B 是 His；Gly；或 L 或 D 芳香族或脂肪族氨基酸；或不含；C 是 (L 或 D) 芳香族或脂肪族氨基酸；X 是 GlyNH2；AlaNH2；氨基乙基；氨基丙基；或氨基羟乙基；Y 是氢或 C1-4 烷基；n 是 2 或 3。 这类肽具有持久的 LHRH 激动剂和拮抗剂活性，可用于促进和降低生育能力。它们可用于合适的药物组合物中。 新型中间体化合物的化学式为 式化合物 通过将式化合物烷基化，必要时去除其中的保护基团，制得： 在这些式子中，A 是氢或 R3-O-CO-，R2 是 C1-4 烷基，R3 是 C1-12 烷基或 C1-4 芳烷基。
• Fused pyrimidine derivatives as A2A / A2B inhibitors
  申请人：Incyte Corporation

  公开号：US11168089B2

  公开（公告）日：2021-11-09

  This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

  本申请涉及式 (I) 化合物： 或其药学上可接受的盐类，它们能调节腺苷受体（如 A2A 和 A2B 亚型受体）的活性，可用于治疗与腺苷受体活性有关的疾病，例如癌症、炎症性疾病、心血管疾病和神经退行性疾病。
• BICYCLO 2.2.2.]OCTANE DERIVATIVES AS CHOLESTOCYSTOKININ INHIBITORS
  申请人：JAMES BLACK FOUNDATION LIMITED

  公开号：EP0626942A1

  公开（公告）日：1994-12-07